Versant Ventures

The new preliminary prospectus offers for sale around 9.6 million shares by shareholders of the firm. Helicos won't receive any proceeds from the sale.

Short Reads

Premium

Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…

Helicos filed the prospectus for 68.4 million shares held by investors who participated in a private placement in December. The firm would receive none of the proceeds from the sale of those shares, if any of them are sold.

scientists may be years away from developing genomics-based medical treatments and therapies, but the hype surrounding the news that rese

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.